{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:11:50Z","timestamp":1793725910572,"version":"4.6.1"},"reference-count":31,"publisher":"Index Copernicus","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Otolaryngol Pol"],"published-print":{"date-parts":[[2025,11,25]]},"abstract":"<ns3:p>&lt;b&gt;Introduction:&lt;\/b&gt; Primary chronic rhinosinusitis with nasal polyps (CRSwNP) is a severe, often uncontrolled disease whose pathomechanism involves type 2 inflammation (T2). Biologic drugs targeting interleukin 4 and 13 (dupilumab) receptors and blocking interleukin 5 (mepolizumab) have been approved for the treatment of the T2 endotype.&lt;b&gt;Aim:&lt;\/b&gt; Presentation of the authors\u2019 suggestions that guided the choice of an appropriate biologic agent when initiating qualification for the treatment of patients with CRSwNP, based on the authors\u2019 experience and data from the literature related to biologic therapy.&lt;b&gt;Materials and methods:&lt;\/b&gt; Patients with CRSwNP were qualified for biological treatment in accordance with the EPOS (European Position Paper on Rhinosinusitis) guidelines and the criteria of the B.156 drug program. The choice of an appropriate biologic was based on medical history data, such as the level of asthma control, presence of allergies, and the occurrence of N-ERD (nonsteroidal anti-inflammatory drug\u2013exacerbated respiratory disease), as well as biomarker results: total IgE concentration and absolute blood eosinophil count.&lt;b&gt;Results:&lt;\/b&gt; The study included 43 patients (23 treated with mepolizumab, 20 treated with dupilumab). Groups of patients were comparable in terms of age, sex, number of sinonasal surgeries, prevalence of asthma, NSAIDs (non-steroidal anti-inflammatory drugs) sensitivity, atopy and initial SNOT-22 (Sinonasal Outcome Test-22), VAS (Visual Analog Scale), NPS (Nasal Polyp Score), and L-K score (Lund-Kennedy score). Eosinophilia total range was 250\u20131000 cells\/microL. Baseline peripheral blood eosinophil count was significantly higher in the mepolizumab-treated group. In the dupilumab-treated group, increases in eosinophil counts up to 3500 cells\/\u03bcl were observed during therapy; however, no patient developed clinical features of hypereosinophilic syndrome.&lt;b&gt;Conclusions:&lt;\/b&gt; When selecting a biologic drug for the treatment of CRSwNP, it is recommended to consider not only the values of available biomarkers, but also the degree of asthma control, the cumulative dose of oral corticosteroids (OCSs), the patient\u2019s age, and treatment convenience for the patient.<\/ns3:p>","DOI":"10.5604\/01.3001.0055.4321","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:55:41Z","timestamp":1768204541000},"page":"1-8","source":"Crossref","is-referenced-by-count":2,"title":["Biologic Therapy for Chronic Rhinosinusitis with Nasal Polyps: Case Analysis and Proposal of a Qualification Scheme"],"prefix":"10.5604","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7967-6887","authenticated-orcid":false,"given":"Gra\u017cyna","family":"Stryjewska-Makuch","sequence":"first","affiliation":[{"name":"Department of Laryngology and Laryngological Oncology, Leszek Giec Upper-Silesian Medical Centre of the Medical University of Silesia, Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9563-4589","authenticated-orcid":false,"given":"Maria","family":"Humeniuk-Arasiewicz","sequence":"additional","affiliation":[{"name":"Department of Laryngology and Laryngological Oncology, Leszek Giec Upper-Silesian Medical Centre of the Medical University of Silesia, Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4507-5113","authenticated-orcid":false,"given":"Marcelina","family":"Niemiec-Urba\u0144czyk","sequence":"additional","affiliation":[{"name":"Department of Laryngology and Laryngological Oncology, Leszek Giec Upper-Silesian Medical Centre of the Medical University of Silesia, Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Michalak-Kolarz","sequence":"additional","affiliation":[{"name":"Department of Laryngology and Laryngological Oncology, Leszek Giec Upper-Silesian Medical Centre of the Medical University of Silesia, Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6339-9053","authenticated-orcid":false,"given":"Joanna","family":"Gl\u0215ck","sequence":"additional","affiliation":[{"name":"Chair and Clinical Department of Internal Diseases, Allergology and Clinical Immunology in Katowice, Medical University of Silesia, Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3689","reference":[{"key":"633646r1","unstructured":"Fokkens W.J., Lund V.J., Hopkins C. et al.: European position paper on rhinosinusitis and nasal polyps 2020. Rhinology., 2020; 58(Suppl S29): 1\u2013464."},{"key":"633646r2","unstructured":"Belliveau P.P.: Omalizumab: a monoclonal anti-IgE antibody. Med Gen Med.,2005; 7(2): 27."},{"key":"633646r3","doi-asserted-by":"crossref","unstructured":"Gevaert P., Calus L., Van Zele T. et al.: Omalizumab is effective in allergic andnonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol.,2013; 131(1): 110-6.e1.","DOI":"10.1016\/j.jaci.2012.07.047"},{"key":"633646r4","unstructured":"Sanofi, FDA approves Dupixent (dupilumab) for chronic rhinosinusitiswith nasal polyposis. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2019\/2019-06-26-17-30-00-1874771 (26.06.2019)."},{"key":"633646r5","unstructured":"Bachert C., Han J.K., Desrosiers M. et al.: Efficacy and safety of dupilumab inpatients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NPSINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet.,2019; 394(10209): 1638\u20131650."},{"key":"633646r6","doi-asserted-by":"crossref","unstructured":"Hopkins C., Han J.K., Fokkens W. et al.: Dupilumab versus mepolizumab forchronic rhinosinusitis with nasal polyposis: an indirect treatment comparison. J Allergy Clin Immunol Pract., 2024; 12(12): 3393-401.e15. doi: 10.1016\/j.jaip.2024.09.015. PMID: 39326524.","DOI":"10.1016\/j.jaip.2024.09.015"},{"key":"633646r7","unstructured":"European Medicines Agency. Nucala: product information. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nucala (03.12.2015)."},{"key":"633646r8","doi-asserted-by":"crossref","unstructured":"Lourijsen E.S., de Borgie C.A., Vleming M., Fokkens W.J.: Endoscopic sinussurgery in adult patients with chronic rhinosinusitis with nasal polyps (PolypESS): study protocol for a randomised controlled trial. Trials., 2017; 18(1): 39.","DOI":"10.1186\/s13063-016-1728-z"},{"key":"633646r9","doi-asserted-by":"crossref","unstructured":"Borish L., Cohen N.A., Chupp G. et al.: Evaluating enrollment and outcomecriteria in trials of biologics for chronic rhinosinusitis with nasal polyps. AnnAllergy Asthma Immunol., 2022; 129(2): 160\u2013168.","DOI":"10.1016\/j.anai.2022.04.004"},{"key":"633646r10","doi-asserted-by":"crossref","unstructured":"Bachert C., Han J.K., Wagenmann M. et al.: EUFOREA expert board meetingon uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP)and biologics: definitions and management. J Allergy Clin Immunol., 2021;147(6): 1981\u20131992.","DOI":"10.1016\/j.jaci.2020.11.013"},{"key":"633646r11","doi-asserted-by":"crossref","unstructured":"Fokkens W.J., Lund V., Bachert C. et al.: EUFOREA consensus on biologics forCRSwNP with or without asthma. Allergy., 2019; 74(12): 2312\u20132319.","DOI":"10.1111\/all.13875"},{"key":"633646r12","doi-asserted-by":"crossref","unstructured":"Alobid I., Col\u00e1s C., Castillo J.A. et al.: Spanish consensus on the managementof chronic rhinosinusitis with nasal polyps (POLIposis NAsal\/POLINA 2.0).J Investig Allergol Clin Immunol., 2023; 33(5): 317\u2013331.","DOI":"10.18176\/jiaci.0910"},{"key":"633646r13","doi-asserted-by":"crossref","unstructured":"Klimek L., F\u00f6rster-Ruhrmann U., Beule A.G. et al.: Indicating biologics forchronic rhinosinusitis with nasal polyps (CRSwNP). Allergo J Int., 2022;31(5): 149\u2013160.","DOI":"10.1007\/s40629-022-00220-x"},{"key":"633646r14","doi-asserted-by":"crossref","unstructured":"Fokkens W.J., Viskens A.S., Backer V. et al.: EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023 Rhinology., 2023; 61(3): 194\u2013202.","DOI":"10.4193\/Rhin22.489"},{"key":"633646r15","doi-asserted-by":"crossref","unstructured":"DeConde A.S., Mace J.C., Bodner T. et al.: SNOT-22 quality of life domainsdifferentially predict treatment modality selection in chronic rhinosinusitis.Int Forum Allergy Rhinol., 2014; 4(12): 972\u2013979.","DOI":"10.1002\/alr.21408"},{"key":"633646r16","doi-asserted-by":"crossref","unstructured":"Chowdhury N.I., Mace J.C., Smith T.L., Rudmik L.: What drives productivityloss in chronic rhinosinusitis? A SNOT-22 subdomain analysis. Laryngoscope., 2018; 128(1): 23\u201330.","DOI":"10.1002\/lary.26723"},{"key":"633646r17","doi-asserted-by":"crossref","unstructured":"Hopkins C., Gillett S., Slack R., Lund V.J., Browne J.P.: Psychometric validity ofthe 22-item Sinonasal Outcome Test. Clin Otolaryngol., 2009; 34(5): 447\u2013454.","DOI":"10.1111\/j.1749-4486.2009.01995.x"},{"key":"633646r18","doi-asserted-by":"crossref","unstructured":"Alobid I., Calvo-Henr\u00edquez C., Viveros-D\u00edez P. et al.: Validation of a visual analog scale for loss of smell as a quick test in chronic rhinosinusitis with nasalpolyps. J Investig Allergol Clin Immunol., 2024; 34(5): 377\u2013384.","DOI":"10.18176\/jiaci.0937"},{"key":"633646r19","doi-asserted-by":"crossref","unstructured":"Lourijsen E.S., de Borgie C.A., Vleming M., Fokkens W.J.: Endoscopic sinus surgery in adult patients with chronic rhinosinusitis with nasal polyps (PolypESS): study protocol for a randomised controlled trial. Trials.,2017; 18(1): 39.","DOI":"10.1186\/s13063-016-1728-z"},{"key":"633646r20","doi-asserted-by":"crossref","unstructured":"Lund V.J., Kennedy D.W.: Quantification for staging sinusitis. The staging andtherapy group. Ann Otol Rhinol Laryngol Suppl., 1995; 167: 17\u201321.","DOI":"10.1177\/000348949510410s02"},{"key":"633646r21","doi-asserted-by":"crossref","unstructured":"Dupin C., Belhadi D., Guilleminault L. et al.: Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centreadult cohort. Clin Exp Allergy., 2020; 50(7): 789\u2013798.","DOI":"10.1111\/cea.13614"},{"key":"633646r22","doi-asserted-by":"crossref","unstructured":"Brusselle G.G., Koppelman G.H.: Biologic therapies for severe asthma. N EnglJ Med., 2022; 386(2): 157\u2013171.","DOI":"10.1056\/NEJMra2032506"},{"key":"633646r23","unstructured":"Kemp P., van der Lans R.J.L., Otten J.J. et al.: Hypereosinophilia during dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps.Rhinology., 2024; 62(3): 202\u2013207."},{"key":"633646r24","doi-asserted-by":"crossref","unstructured":"Wechsler M.E., Klion A.D., Paggiaro P. et al.: Effect of dupilumab on bloodeosinophil counts in patients with asthma, chronic rhinosinusitis with nasalpolyps, atopic dermatitis, or eosinophilic esophagitis. J Allergy Clin ImmunolPract., 2022; 10(9): 2695\u20132709.","DOI":"10.1016\/j.jaip.2022.05.019"},{"key":"633646r25","doi-asserted-by":"crossref","unstructured":"Zhu J.: T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2)development and regulation of interleukin-4 (IL-4) and IL-13 production. Cytokine., 2015; 75(1): 14\u201324.","DOI":"10.1016\/j.cyto.2015.05.010"},{"key":"633646r26","doi-asserted-by":"crossref","unstructured":"Lombardi C., Berti A., Cottini M.: The emerging roles of eosinophils: implications for the targeted treatment of eosinophilic-associated inflammatoryconditions. Curr Res Immunol., 2022; 3: 42\u201353.","DOI":"10.1016\/j.crimmu.2022.03.002"},{"key":"633646r27","doi-asserted-by":"crossref","unstructured":"Bachert C., Corren J., Lee S.E. et al.: Dupilumab efficacy and biomarkers inchronic rhinosinusitis with nasal polyps: association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation inthe phase 3 SINUS-24 and SINUS-52 trials. Int Forum Allergy Rhinol., 2022;12(9): 1191\u20131195.","DOI":"10.1002\/alr.22964"},{"key":"633646r28","doi-asserted-by":"crossref","unstructured":"Eger K., Pet L., Weersink E.J.M., Bel E.H.: Complications of switching fromanti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma. J Allergy Clin Immunol Pract., 2021; 9(8): 2913\u20132915.","DOI":"10.1016\/j.jaip.2021.02.042"},{"key":"633646r29","doi-asserted-by":"crossref","unstructured":"Stryjewska-Makuch G., Humeniuk-Arasiewicz M., Kokoszka M., GoroszkiewiczK., Gluck J.: Relationship between blood eosinophilia and disease severity in chronic rhinosinusitis with nasal polyps. Pol Arch Intern Med., 2024; 134(1): 16740.","DOI":"10.20452\/pamw.16740"},{"key":"633646r30","doi-asserted-by":"crossref","unstructured":"Jiang S., Duong H., Mohindra V.: Dupilumab-induced hypereosinophilia: a clinical challenge and case series of an unpredictable complication. Ann AllergyAsthma Immunol., 2023; 131(2): 134.","DOI":"10.1016\/j.anai.2023.08.404"},{"key":"633646r31","doi-asserted-by":"crossref","unstructured":"Jameson J.L., Longo D.L.: Precision medicine \u2013 personalized, problematic, andpromising. N Engl J Med., 2015; 372(23): 2229\u20132234.","DOI":"10.1056\/NEJMsb1503104"}],"container-title":["Otolaryngologia Polska"],"original-title":[],"link":[{"URL":"https:\/\/otolaryngologypl.com\/gicid\/pdf\/01.3001.0055.4321","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/otolaryngologypl.com\/gicid\/pdf\/01.3001.0055.4321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:55:57Z","timestamp":1768204557000},"score":1,"resource":{"primary":{"URL":"https:\/\/otolaryngologypl.com\/gicid\/01.3001.0055.4321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12,14]]}},"URL":"https:\/\/doi.org\/10.5604\/01.3001.0055.4321","relation":{},"ISSN":["0030-6657","2300-8423"],"issn-type":[{"value":"0030-6657","type":"print"},{"value":"2300-8423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]}}}